Zimmer Biomet Holdings, Inc. (NYSE: ZBH) Stock Competitors & Peer Comparison
See ZBH's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ZBH and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZBH | $94.99 | +0.01% | 18.1B | 11.20 | $8.48 | +1.01% |
| ABT | $104.06 | -0.79% | 180.1B | 19.97 | $5.21 | +2.40% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $92.77 | -2.09% | 118.6B | 16.77 | $5.53 | +3.02% |
| SYK | $297.94 | +1.11% | 114.3B | 22.26 | $13.39 | +1.20% |
| BSX | $45.05 | +1.49% | 65.3B | 14.53 | $3.10 | N/A |
| EW | $87.22 | +0.72% | 50.3B | 32.30 | $2.70 | N/A |
| DXCM | $85.98 | -0.07% | 32.4B | 33.72 | $2.55 | N/A |
| GEHC | $69.76 | +0.27% | 31.5B | 15.30 | $4.56 | +0.20% |
| PHG | $25.50 | -0.93% | 24.9B | 14.57 | $1.75 | +3.84% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
ZBH vs ABT Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, ABT has a market cap of 180.1B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while ABT trades at $104.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas ABT's P/E ratio is 19.97. In terms of profitability, ZBH's ROE is +0.06%, compared to ABT's ROE of +0.11%. Regarding short-term risk, ZBH is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
ZBH vs BSX-PA Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ZBH's ROE is +0.06%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ZBH is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BSX-PA's competition here
Medtronic Plc (NYSE: MDT)
ZBH vs MDT Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, MDT has a market cap of 118.6B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while MDT trades at $92.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas MDT's P/E ratio is 16.77. In terms of profitability, ZBH's ROE is +0.06%, compared to MDT's ROE of +0.11%. Regarding short-term risk, ZBH is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
ZBH vs SYK Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, SYK has a market cap of 114.3B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while SYK trades at $297.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas SYK's P/E ratio is 22.26. In terms of profitability, ZBH's ROE is +0.06%, compared to SYK's ROE of +0.16%. Regarding short-term risk, ZBH is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
ZBH vs BSX Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, BSX has a market cap of 65.3B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while BSX trades at $45.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas BSX's P/E ratio is 14.53. In terms of profitability, ZBH's ROE is +0.06%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ZBH is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
ZBH vs EW Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, EW has a market cap of 50.3B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while EW trades at $87.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas EW's P/E ratio is 32.30. In terms of profitability, ZBH's ROE is +0.06%, compared to EW's ROE of +0.10%. Regarding short-term risk, ZBH is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
ZBH vs DXCM Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, DXCM has a market cap of 32.4B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while DXCM trades at $85.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas DXCM's P/E ratio is 33.72. In terms of profitability, ZBH's ROE is +0.06%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, ZBH is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
ZBH vs GEHC Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, GEHC has a market cap of 31.5B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while GEHC trades at $69.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas GEHC's P/E ratio is 15.30. In terms of profitability, ZBH's ROE is +0.06%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, ZBH is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
ZBH vs PHG Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, PHG has a market cap of 24.9B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while PHG trades at $25.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas PHG's P/E ratio is 14.57. In terms of profitability, ZBH's ROE is +0.06%, compared to PHG's ROE of +0.10%. Regarding short-term risk, ZBH is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check PHG's competition here
Abiomed, Inc. (NASDAQ: ABMD)
ZBH vs ABMD Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ZBH's ROE is +0.06%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ZBH is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
ZBH vs PEN Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while PEN trades at $322.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas PEN's P/E ratio is 84.20. In terms of profitability, ZBH's ROE is +0.06%, compared to PEN's ROE of +0.11%. Regarding short-term risk, ZBH is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
ZBH vs SWAV Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ZBH's ROE is +0.06%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ZBH is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
ZBH vs SNN Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, SNN has a market cap of 12.1B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while SNN trades at $28.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas SNN's P/E ratio is 19.47. In terms of profitability, ZBH's ROE is +0.06%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ZBH is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
ZBH vs ALGN Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, ALGN has a market cap of 10.6B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while ALGN trades at $149.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas ALGN's P/E ratio is 13.58. In terms of profitability, ZBH's ROE is +0.06%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, ZBH is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
ZBH vs GMED Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, GMED has a market cap of 10.2B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while GMED trades at $75.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas GMED's P/E ratio is 17.04. In terms of profitability, ZBH's ROE is +0.06%, compared to GMED's ROE of +0.12%. Regarding short-term risk, ZBH is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
ZBH vs GKOS Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, GKOS has a market cap of 9.8B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while GKOS trades at $166.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas GKOS's P/E ratio is -194.09. In terms of profitability, ZBH's ROE is +0.06%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, ZBH is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
ZBH vs PODD Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, PODD has a market cap of 9.8B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while PODD trades at $141.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas PODD's P/E ratio is 24.18. In terms of profitability, ZBH's ROE is +0.06%, compared to PODD's ROE of +0.27%. Regarding short-term risk, ZBH is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
ZBH vs BIO Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, BIO has a market cap of 9.4B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while BIO trades at $352.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas BIO's P/E ratio is 38.01. In terms of profitability, ZBH's ROE is +0.06%, compared to BIO's ROE of +0.03%. Regarding short-term risk, ZBH is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check BIO's competition here
Masimo Corporation (NASDAQ: MASI)
ZBH vs MASI Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas MASI's P/E ratio is 44.43. In terms of profitability, ZBH's ROE is +0.06%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ZBH is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check MASI's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
ZBH vs BIO-B Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, BIO-B has a market cap of 9.4B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while BIO-B trades at $354.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas BIO-B's P/E ratio is -62.35. In terms of profitability, ZBH's ROE is +0.06%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, ZBH is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check BIO-B's competition here
Bruker Corporation (NASDAQ: BRKR)
ZBH vs BRKR Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, BRKR has a market cap of 8.4B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while BRKR trades at $55.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas BRKR's P/E ratio is 27.82. In terms of profitability, ZBH's ROE is +0.06%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, ZBH is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
ZBH vs BRKRP Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, BRKRP has a market cap of 8.4B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while BRKRP trades at $410.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas BRKRP's P/E ratio is 222.61. In terms of profitability, ZBH's ROE is +0.06%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, ZBH is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check BRKRP's competition here
Haemonetics Corporation (NYSE: HAE)
ZBH vs HAE Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, HAE has a market cap of 5.4B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while HAE trades at $118.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas HAE's P/E ratio is 23.70. In terms of profitability, ZBH's ROE is +0.06%, compared to HAE's ROE of +0.11%. Regarding short-term risk, ZBH is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
ZBH vs NARI Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas NARI's P/E ratio is -59.24. In terms of profitability, ZBH's ROE is +0.06%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ZBH is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
ZBH vs ITGR Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while ITGR trades at $126.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas ITGR's P/E ratio is 19.96. In terms of profitability, ZBH's ROE is +0.06%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, ZBH is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
ZBH vs LIVN Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while LIVN trades at $78.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas LIVN's P/E ratio is 18.56. In terms of profitability, ZBH's ROE is +0.06%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, ZBH is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
ZBH vs IRTC Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while IRTC trades at $109.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas IRTC's P/E ratio is -254.88. In terms of profitability, ZBH's ROE is +0.06%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, ZBH is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check IRTC's competition here
Neogen Corporation (NASDAQ: NEOG)
ZBH vs NEOG Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, NEOG has a market cap of 2.5B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while NEOG trades at $11.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas NEOG's P/E ratio is 41.50. In terms of profitability, ZBH's ROE is +0.06%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, ZBH is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check NEOG's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
ZBH vs TMDX Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while TMDX trades at $71.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas TMDX's P/E ratio is 36.35. In terms of profitability, ZBH's ROE is +0.06%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, ZBH is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check TMDX's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
ZBH vs UFPT Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while UFPT trades at $293.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas UFPT's P/E ratio is 29.95. In terms of profitability, ZBH's ROE is +0.06%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ZBH is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
ZBH vs NUVA Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ZBH's ROE is +0.06%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ZBH is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check NUVA's competition here
AxoGen, Inc. (NASDAQ: AXGN)
ZBH vs AXGN Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, AXGN has a market cap of 2.1B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while AXGN trades at $35.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas AXGN's P/E ratio is 92.67. In terms of profitability, ZBH's ROE is +0.06%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, ZBH is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check AXGN's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
ZBH vs INSP Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, INSP has a market cap of 2B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while INSP trades at $70.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas INSP's P/E ratio is 30.89. In terms of profitability, ZBH's ROE is +0.06%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ZBH is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check INSP's competition here
Butterfly Network, Inc. (NYSE: BFLY)
ZBH vs BFLY Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, BFLY has a market cap of 2B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while BFLY trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas BFLY's P/E ratio is -31.15. In terms of profitability, ZBH's ROE is +0.06%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, ZBH is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BFLY's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
ZBH vs ESTA Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, ESTA has a market cap of 1.7B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while ESTA trades at $58.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas ESTA's P/E ratio is -46.21. In terms of profitability, ZBH's ROE is +0.06%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, ZBH is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
ZBH vs NVCR Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, NVCR has a market cap of 1.7B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while NVCR trades at $14.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas NVCR's P/E ratio is -11.45. In terms of profitability, ZBH's ROE is +0.06%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, ZBH is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
ZBH vs ATEC Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while ATEC trades at $10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas ATEC's P/E ratio is -173.50. In terms of profitability, ZBH's ROE is +0.06%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, ZBH is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check ATEC's competition here
Picard Medical, Inc. (AMEX: PMI)
ZBH vs PMI Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, PMI has a market cap of 1.6B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while PMI trades at $15.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas PMI's P/E ratio is -12.84. In terms of profitability, ZBH's ROE is +0.06%, compared to PMI's ROE of -9.31%. Regarding short-term risk, ZBH is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check PMI's competition here
CONMED Corporation (NYSE: CNMD)
ZBH vs CNMD Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while CNMD trades at $46.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas CNMD's P/E ratio is 10.12. In terms of profitability, ZBH's ROE is +0.06%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, ZBH is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
ZBH vs HSKA Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ZBH's ROE is +0.06%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ZBH is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check HSKA's competition here
Avanos Medical, Inc. (NYSE: AVNS)
ZBH vs AVNS Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas AVNS's P/E ratio is 27.77. In terms of profitability, ZBH's ROE is +0.06%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ZBH is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check AVNS's competition here
Enovis Corporation (NYSE: ENOV)
ZBH vs ENOV Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while ENOV trades at $19.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas ENOV's P/E ratio is 5.70. In terms of profitability, ZBH's ROE is +0.06%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, ZBH is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check ENOV's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
ZBH vs TNDM Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while TNDM trades at $16.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas TNDM's P/E ratio is -17.61. In terms of profitability, ZBH's ROE is +0.06%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, ZBH is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check TNDM's competition here
IRadimed Corporation (NASDAQ: IRMD)
ZBH vs IRMD Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while IRMD trades at $87.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas IRMD's P/E ratio is 44.05. In terms of profitability, ZBH's ROE is +0.06%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ZBH is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check IRMD's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
ZBH vs SILK Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas SILK's P/E ratio is -18.96. In terms of profitability, ZBH's ROE is +0.06%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ZBH is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
ZBH vs FNA Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas FNA's P/E ratio is -19.83. In terms of profitability, ZBH's ROE is +0.06%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ZBH is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check FNA's competition here
Artivion, Inc. (NYSE: AORT)
ZBH vs AORT Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while AORT trades at $22.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas AORT's P/E ratio is 37.08. In terms of profitability, ZBH's ROE is +0.06%, compared to AORT's ROE of -0.01%. Regarding short-term risk, ZBH is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check AORT's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
ZBH vs IART Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, IART has a market cap of 1B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while IART trades at $13.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas IART's P/E ratio is 5.70. In terms of profitability, ZBH's ROE is +0.06%, compared to IART's ROE of -0.01%. Regarding short-term risk, ZBH is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check IART's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
ZBH vs PRCT Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, PRCT has a market cap of 1B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while PRCT trades at $18.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas PRCT's P/E ratio is -9.42. In terms of profitability, ZBH's ROE is +0.06%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, ZBH is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
ZBH vs LMRI Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, LMRI has a market cap of 1B. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while LMRI trades at $10.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas LMRI's P/E ratio is -20.86. In terms of profitability, ZBH's ROE is +0.06%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, ZBH is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check LMRI's competition here
CeriBell, Inc. (NASDAQ: CBLL)
ZBH vs CBLL Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, CBLL has a market cap of 997.8M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while CBLL trades at $26.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas CBLL's P/E ratio is -14.77. In terms of profitability, ZBH's ROE is +0.06%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, ZBH is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CBLL's competition here
Bioventus Inc. (NASDAQ: BVS)
ZBH vs BVS Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, BVS has a market cap of 921.4M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while BVS trades at $13.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas BVS's P/E ratio is 17.75. In terms of profitability, ZBH's ROE is +0.06%, compared to BVS's ROE of +0.28%. Regarding short-term risk, ZBH is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BVS's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
ZBH vs SIBN Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, SIBN has a market cap of 881.1M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while SIBN trades at $19.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas SIBN's P/E ratio is -57.82. In terms of profitability, ZBH's ROE is +0.06%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, ZBH is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check SIBN's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
ZBH vs CSII Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas CSII's P/E ratio is -20.83. In terms of profitability, ZBH's ROE is +0.06%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ZBH is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check CSII's competition here
InMode Ltd. (NASDAQ: INMD)
ZBH vs INMD Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, INMD has a market cap of 809.6M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while INMD trades at $14.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas INMD's P/E ratio is 9.77. In terms of profitability, ZBH's ROE is +0.06%, compared to INMD's ROE of +0.12%. Regarding short-term risk, ZBH is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check INMD's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
ZBH vs AHCO Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, AHCO has a market cap of 801.7M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while AHCO trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas AHCO's P/E ratio is 12.00. In terms of profitability, ZBH's ROE is +0.06%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, ZBH is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check AHCO's competition here
Varex Imaging Corporation (NASDAQ: VREX)
ZBH vs VREX Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, VREX has a market cap of 781.3M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while VREX trades at $18.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas VREX's P/E ratio is 19.37. In terms of profitability, ZBH's ROE is +0.06%, compared to VREX's ROE of +0.05%. Regarding short-term risk, ZBH is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check VREX's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
ZBH vs BBNX Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, BBNX has a market cap of 757.6M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while BBNX trades at $16.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas BBNX's P/E ratio is -10.21. In terms of profitability, ZBH's ROE is +0.06%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, ZBH is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BBNX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
ZBH vs CTKB Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, CTKB has a market cap of 682.4M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while CTKB trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas CTKB's P/E ratio is -27.81. In terms of profitability, ZBH's ROE is +0.06%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, ZBH is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CTKB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
ZBH vs SRDX Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ZBH's ROE is +0.06%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, ZBH is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SRDX's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
ZBH vs AVR Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, AVR has a market cap of 601.8M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while AVR trades at $6.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas AVR's P/E ratio is -3.18. In terms of profitability, ZBH's ROE is +0.06%, compared to AVR's ROE of -0.78%. Regarding short-term risk, ZBH is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check AVR's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
ZBH vs APEN Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas APEN's P/E ratio is -9.43. In terms of profitability, ZBH's ROE is +0.06%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ZBH is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check APEN's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
ZBH vs KIDS Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, KIDS has a market cap of 576.2M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while KIDS trades at $22.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas KIDS's P/E ratio is -18.70. In terms of profitability, ZBH's ROE is +0.06%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, ZBH is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check KIDS's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
ZBH vs PACB Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, PACB has a market cap of 570.4M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while PACB trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas PACB's P/E ratio is -4.48. In terms of profitability, ZBH's ROE is +0.06%, compared to PACB's ROE of -49.62%. Regarding short-term risk, ZBH is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check PACB's competition here
ZimVie Inc. (NASDAQ: ZIMV)
ZBH vs ZIMV Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ZBH's ROE is +0.06%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, ZBH is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ZIMV's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
ZBH vs TCMD Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, TCMD has a market cap of 515.1M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while TCMD trades at $22.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas TCMD's P/E ratio is 21.06. In terms of profitability, ZBH's ROE is +0.06%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, ZBH is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check TCMD's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
ZBH vs DCTH Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, DCTH has a market cap of 498.6M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while DCTH trades at $14.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas DCTH's P/E ratio is 1437.00. In terms of profitability, ZBH's ROE is +0.06%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, ZBH is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check DCTH's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
ZBH vs SSII Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, SSII has a market cap of 491.2M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while SSII trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas SSII's P/E ratio is -40.83. In terms of profitability, ZBH's ROE is +0.06%, compared to SSII's ROE of -0.27%. Regarding short-term risk, ZBH is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check SSII's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
ZBH vs SGHT Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, SGHT has a market cap of 455M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while SGHT trades at $8.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas SGHT's P/E ratio is -14.75. In terms of profitability, ZBH's ROE is +0.06%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, ZBH is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check SGHT's competition here
Cerus Corporation (NASDAQ: CERS)
ZBH vs CERS Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, CERS has a market cap of 447.4M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while CERS trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas CERS's P/E ratio is -73.75. In terms of profitability, ZBH's ROE is +0.06%, compared to CERS's ROE of -0.10%. Regarding short-term risk, ZBH is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
ZBH vs NPCE Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, NPCE has a market cap of 438.3M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while NPCE trades at $12.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas NPCE's P/E ratio is -22.40. In terms of profitability, ZBH's ROE is +0.06%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, ZBH is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check NPCE's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
ZBH vs SENS Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, SENS has a market cap of 424M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while SENS trades at $8.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas SENS's P/E ratio is -3.60. In terms of profitability, ZBH's ROE is +0.06%, compared to SENS's ROE of -1.66%. Regarding short-term risk, ZBH is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
ZBH vs OFIX Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, OFIX has a market cap of 387.6M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while OFIX trades at $9.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas OFIX's P/E ratio is -6.25. In terms of profitability, ZBH's ROE is +0.06%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, ZBH is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check OFIX's competition here
CapsoVision, Inc. (NASDAQ: CV)
ZBH vs CV Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, CV has a market cap of 354.9M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while CV trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas CV's P/E ratio is -10.59. In terms of profitability, ZBH's ROE is +0.06%, compared to CV's ROE of -1.78%. Regarding short-term risk, ZBH is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CV's competition here
Avita Medical Inc. (NASDAQ: RCEL)
ZBH vs RCEL Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, RCEL has a market cap of 326.4M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while RCEL trades at $13.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas RCEL's P/E ratio is -9.12. In terms of profitability, ZBH's ROE is +0.06%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, ZBH is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check RCEL's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
ZBH vs SMLR Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ZBH's ROE is +0.06%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, ZBH is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check SMLR's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
ZBH vs CLPT Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, CLPT has a market cap of 279.7M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while CLPT trades at $9.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas CLPT's P/E ratio is -7.77. In terms of profitability, ZBH's ROE is +0.06%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, ZBH is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CLPT's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
ZBH vs INFU Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, INFU has a market cap of 273.9M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while INFU trades at $13.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas INFU's P/E ratio is 33.54. In terms of profitability, ZBH's ROE is +0.06%, compared to INFU's ROE of +0.15%. Regarding short-term risk, ZBH is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check INFU's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
ZBH vs TMCI Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, TMCI has a market cap of 252.3M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while TMCI trades at $3.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas TMCI's P/E ratio is -4.13. In terms of profitability, ZBH's ROE is +0.06%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, ZBH is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check TMCI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
ZBH vs CATX Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, CATX has a market cap of 252.3M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while CATX trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas CATX's P/E ratio is -1.66. In terms of profitability, ZBH's ROE is +0.06%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ZBH is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check CATX's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
ZBH vs MGRM Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas MGRM's P/E ratio is -12.00. In terms of profitability, ZBH's ROE is +0.06%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, ZBH is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
ZBH vs ELMD Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, ELMD has a market cap of 228.1M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while ELMD trades at $27.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas ELMD's P/E ratio is 21.02. In terms of profitability, ZBH's ROE is +0.06%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, ZBH is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
ZBH vs NVRO Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ZBH's ROE is +0.06%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ZBH is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check NVRO's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
ZBH vs TLSI Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, TLSI has a market cap of 217.4M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while TLSI trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas TLSI's P/E ratio is -2.10. In terms of profitability, ZBH's ROE is +0.06%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, ZBH is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check TLSI's competition here
Quantum-Si incorporated (NASDAQ: QSI)
ZBH vs QSI Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, QSI has a market cap of 215.9M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while QSI trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas QSI's P/E ratio is -2.36. In terms of profitability, ZBH's ROE is +0.06%, compared to QSI's ROE of -0.47%. Regarding short-term risk, ZBH is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check QSI's competition here
Profound Medical Corp. (NASDAQ: PROF)
ZBH vs PROF Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, PROF has a market cap of 214.1M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while PROF trades at $5.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas PROF's P/E ratio is -5.98. In terms of profitability, ZBH's ROE is +0.06%, compared to PROF's ROE of -0.56%. Regarding short-term risk, ZBH is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
ZBH vs RXST Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, RXST has a market cap of 195.1M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while RXST trades at $4.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas RXST's P/E ratio is -4.15. In terms of profitability, ZBH's ROE is +0.06%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ZBH is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
ZBH vs BSGM Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ZBH's ROE is +0.06%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, ZBH is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
ZBH vs MDGS Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ZBH's ROE is +0.06%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ZBH is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check MDGS's competition here
Inogen, Inc. (NASDAQ: INGN)
ZBH vs INGN Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, INGN has a market cap of 173.8M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while INGN trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas INGN's P/E ratio is -7.20. In terms of profitability, ZBH's ROE is +0.06%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ZBH is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check INGN's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
ZBH vs QIPT Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ZBH's ROE is +0.06%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, ZBH is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
ZBH vs FOCL Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, FOCL has a market cap of 155.9M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while FOCL trades at $4.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas FOCL's P/E ratio is -4.02. In terms of profitability, ZBH's ROE is +0.06%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, ZBH is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check FOCL's competition here
Neuronetics, Inc. (NASDAQ: STIM)
ZBH vs STIM Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, STIM has a market cap of 145.5M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while STIM trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas STIM's P/E ratio is -4.34. In terms of profitability, ZBH's ROE is +0.06%, compared to STIM's ROE of -1.51%. Regarding short-term risk, ZBH is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check STIM's competition here
Quanterix Corporation (NASDAQ: QTRX)
ZBH vs QTRX Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, QTRX has a market cap of 131.2M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while QTRX trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas QTRX's P/E ratio is -1.09. In terms of profitability, ZBH's ROE is +0.06%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, ZBH is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check QTRX's competition here
Owlet, Inc. (NYSE: OWLT)
ZBH vs OWLT Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, OWLT has a market cap of 121M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while OWLT trades at $4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas OWLT's P/E ratio is -29.57. In terms of profitability, ZBH's ROE is +0.06%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, ZBH is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check OWLT's competition here
iCAD, Inc. (NASDAQ: ICAD)
ZBH vs ICAD Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ZBH's ROE is +0.06%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, ZBH is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
ZBH vs HJLI Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas HJLI's P/E ratio is N/A. In terms of profitability, ZBH's ROE is +0.06%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, ZBH is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
ZBH vs ASXC Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas ASXC's P/E ratio is -1.12. In terms of profitability, ZBH's ROE is +0.06%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, ZBH is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for ZBH.Check ASXC's competition here
Neovasc Inc. (NASDAQ: NVCN)
ZBH vs NVCN Comparison October 2026
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBH stands at 18.1B. In comparison, NVCN has a market cap of 82.9M. Regarding current trading prices, ZBH is priced at $94.99 on the NYSE, while NVCN trades at $30.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBH currently has a P/E ratio of 11.20, whereas NVCN's P/E ratio is -1.99. In terms of profitability, ZBH's ROE is +0.06%, compared to NVCN's ROE of -1.21%. Regarding short-term risk, ZBH is less volatile compared to NVCN. This indicates lower risk in terms of short-term price fluctuations for ZBH.Check NVCN's competition here